Immunocore reports preliminary 2023 KIMMTRAK revenue of $235M, announces $300M convertible notes offering

Immunocore Holdings plc

Q4 2023 KIMMTRAK net sales ~$66M; full-year 2023 net sales ~$235M.
Cash and equivalents at Dec 31, 2023 ~$443M.
Proposed $300M convertible senior notes due 2030; initial purchasers option for additional $45M.
Net proceeds to accelerate clinical pipeline, expand commercial, and repay Pharmakon loans.
Pipeline: tebentafusp Phase 2/3 cutaneous melanoma topline data expected Q4 2024; IMC-F106C Phase 3 first-line melanoma trial first patient randomization Q1 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immunocore Holdings plc reported the fourth quarter of 2023 and the full year 2023 results: revenue approximately $66 million.

Period: the fourth quarter of 2023 and the full year 2023
Revenue: approximately $66 million
Result: preliminary results

Exact text from the filing

Immunocore Holdings plc (the “Company”) expects to report preliminary unaudited net product revenue (“net sales”) arising from the sales of KIMMTRAK (tebentafusp) of approximately $66 million for the fourth quarter of 2023 and approximately $235 million for the full year 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunocore Holdings plc filing history →

Source: SEC EDGAR

accession 0001140361-24-004321

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.